Eslicarbazepine
| Interaction Color Code | Clinical Bottom Line | Clinical Effects | Drug 1 effect | Drug 2 dose | Drug 2 effect | Management | |
|---|---|---|---|---|---|---|---|
| Lenacapavir Eslicarbazepine | Red: Avoid combination | Do not coadminister: reduced levels of lenacapavir | Potential loss of antiviral efficacy |
Use alternative agents. |
|||
| Darunavir Eslicarbazepine 978 | Orange: Minimal data to guide interaction | Minimal data to guide interaction: risks likely to outweigh benefits | Potential loss of antiviral efficacy |
Consider alternate anticonvulsants. If coadministering, use caution and clinical monitoring is recommended |
|||
| Cabotegravir Eslicarbazepine 335 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of CAB | Potential decrease in antiretroviral efficacy |
Not studied |
Not studied |
Contraindicated. Use alternative agents. |
|
| Raltegravir Eslicarbazepine 318 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of raltegravir | Potential decrease in antiretroviral efficacy |
Use alternative agents |
|||
| Elvitegravir Eslicarbazepine 218 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of elvitegravir | Potential decrease in antiretroviral efficacy |
Contraindicated. Use alternative agents. |
|||
| Bictegravir Eslicarbazepine 75 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of BIC and TAF | Potential decrease in antiretroviral efficacy |
Contraindicated. Use alternative agents. |
|||
| Maraviroc Eslicarbazepine 61 | Orange: Minimal data to guide interaction | Minimal data to guide interaction: risks likely to outweigh benefits | Potential decrease in antiretroviral efficacy |
Use alternative agents |

